How much revenue does Chongqing Lummy Pharmaceutical make?

Chongqing Lummy Pharmaceutical reported 775.69 million CNY in revenue for fiscal year 2025, down 2.5% from 795.60 million CNY in fiscal year 2024. In Q1 2026 revenue was 182.21 million CNY.

What is Chongqing Lummy Pharmaceutical's largest business segment?

Pharmaceutical Manufacturing, with 590.72 million CNY or 78% of segment revenue in fiscal year 2025. Next: Pharmaceutical Distribution (20%) and Service income (3%).

What companies are similar to Chongqing Lummy Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS), Changzhou Qianhong Biopharma Co.,ltd (002550.SZ), Beijing Foyou Pharma Co.,ltd (601089.SS), Dezhan Healthcare Company Limited (000813.SZ).

Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) Stock

About Chongqing Lummy Pharmaceutical Co., Ltd.

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. The c...

At a glance

Chongqing Lummy Pharmaceutical reported revenue of 775.69 million CNY for fiscal year 2025, down 2.5% from fiscal year 2024, and net income of -134.71 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 182.21 million CNY, down 8.2% from a year before. Its largest business segment, Pharmaceutical Manufacturing, brought in 78% of segment revenue in fiscal year 2025.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.